CL2022000294A1 - Composiciones biofarmacéuticas y procedimientos conexos. - Google Patents

Composiciones biofarmacéuticas y procedimientos conexos.

Info

Publication number
CL2022000294A1
CL2022000294A1 CL2022000294A CL2022000294A CL2022000294A1 CL 2022000294 A1 CL2022000294 A1 CL 2022000294A1 CL 2022000294 A CL2022000294 A CL 2022000294A CL 2022000294 A CL2022000294 A CL 2022000294A CL 2022000294 A1 CL2022000294 A1 CL 2022000294A1
Authority
CL
Chile
Prior art keywords
related procedures
biopharmaceutical compositions
compositions
biopharmaceutical
bcma
Prior art date
Application number
CL2022000294A
Other languages
English (en)
Inventor
James K Kranz
Michael Joseph Molloy
Jr Joseph V Rinella
Elizabeth Rae Schmidt
Hillary Amber Schuessler
Tejash Shah
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2022000294A1 publication Critical patent/CL2022000294A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Abstract

La invención aquí descrita proporciona composiciones que comprenden proteínas de unión a antígenos anti-BCMA y procedimientos relacionados para el tratamiento de enfermedades o trastornos mediados por la BCMA
CL2022000294A 2019-08-06 2022-02-04 Composiciones biofarmacéuticas y procedimientos conexos. CL2022000294A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962883451P 2019-08-06 2019-08-06
US201962948432P 2019-12-16 2019-12-16
US202062984110P 2020-03-02 2020-03-02

Publications (1)

Publication Number Publication Date
CL2022000294A1 true CL2022000294A1 (es) 2022-10-07

Family

ID=71994687

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000294A CL2022000294A1 (es) 2019-08-06 2022-02-04 Composiciones biofarmacéuticas y procedimientos conexos.

Country Status (14)

Country Link
US (1) US20220289859A1 (es)
EP (1) EP4010372A2 (es)
JP (2) JP2022543273A (es)
KR (1) KR20220041915A (es)
CN (1) CN114502593A (es)
AU (1) AU2020325753A1 (es)
BR (1) BR112022002236A2 (es)
CA (1) CA3146471A1 (es)
CL (1) CL2022000294A1 (es)
CO (1) CO2022002627A2 (es)
IL (1) IL290325A (es)
MX (1) MX2022001626A (es)
TW (2) TW202120549A (es)
WO (1) WO2021024133A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3227515A1 (en) * 2021-08-03 2023-02-09 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
EP1896503B1 (en) 2005-05-31 2014-10-29 Board of Regents, The University of Texas System IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
US9242013B2 (en) 2010-04-15 2016-01-26 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
RS64791B1 (sr) 2011-05-27 2023-11-30 Glaxo Group Ltd Bcma (cd269/tnfrsf17) - vezujući proteini
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9765342B2 (en) 2012-04-11 2017-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
ES2937015T3 (es) 2012-11-01 2023-03-23 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Anticuerpo contra CD269 (BCMA)
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
AU2014240012A1 (en) 2013-03-15 2015-09-24 Abbvie Inc. Antibody drug conjugate (ADC) purification
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
JP6529188B2 (ja) 2013-11-25 2019-06-12 シアトル ジェネティックス， インコーポレイテッド コンジュゲーションのためのｃｈｏ細胞培養物からの抗体の調製
CA2945620C (en) 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
JP6285274B2 (ja) 2014-04-28 2018-02-28 株式会社ブリヂストン バイアスタイヤ及びその製造方法
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
AU2015292590B2 (en) 2014-07-24 2020-01-16 2Seventy Bio, Inc. BCMA chimeric antigen receptors
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3872094A3 (en) 2014-12-05 2021-12-08 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
KR20170109538A (ko) 2014-12-05 2017-09-29 메모리얼 슬로안-케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 키메라 항원 수용체 및 그의 용도
KR102405104B1 (ko) * 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
KR20180042271A (ko) 2015-08-03 2018-04-25 잉맵 에스에이알엘 Bcma에 대응하는 단일클론 항체
EP3147954A1 (en) 2015-09-22 2017-03-29 Nokia Technologies Oy Photodetector with conductive channel made from two dimensional material and its manufacturing method
EP3691682A1 (en) * 2017-09-14 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells

Also Published As

Publication number Publication date
MX2022001626A (es) 2022-03-02
TW202227142A (zh) 2022-07-16
JP2022543273A (ja) 2022-10-11
CA3146471A1 (en) 2021-02-11
CO2022002627A2 (es) 2022-04-08
US20220289859A1 (en) 2022-09-15
BR112022002236A2 (pt) 2022-05-03
WO2021024133A2 (en) 2021-02-11
IL290325A (en) 2022-04-01
WO2021024133A3 (en) 2021-03-25
JP2024056791A (ja) 2024-04-23
CN114502593A (zh) 2022-05-13
EP4010372A2 (en) 2022-06-15
TW202120549A (zh) 2021-06-01
AU2020325753A1 (en) 2022-03-03
KR20220041915A (ko) 2022-04-01

Similar Documents

Publication Publication Date Title
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
MX2020004555A (es) Moduladores de la vía de estrés integrada.
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
MX2020004558A (es) Moduladores de la vía de estrés integrada.
MX2020004551A (es) Moduladores de la vía de estrés integrada.
MX2020004557A (es) Moduladores de la vía de estrés integrada.
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
MX2020004534A (es) Moduladores de la vía integrada del estrés.
MX2020004537A (es) Moduladores de la vía integrada del estrés.
CO2021006098A2 (es) Moduladores de profármacos de la vía de estrés integrada
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2021000163A1 (es) Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139)
EA201990949A1 (ru) Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
BR112022012230A2 (pt) Variantes de progranulina
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
BR112022000855A2 (pt) Moduladores de nlrp3